Arrow Therapeutics Ltd. (11137618) is a privately owned UK biotechnology company focused on the discovery and development of anti-viral therapies.
Recently, AstraZeneca (LON: AZN) announced its agreement to acquire Arrow Therapeutics, purchasing the company’s total share capital for US$150 Million cash (subject to debt and working capital adjustment), the transaction is expected to close early this year.
An important strategic step for AstraZeneca, the acquisition strengthens its portfolio of promising anti-infective treatments.
Find more details from the press release.The acquisition of Arrow Therapeutics augments AstraZeneca's portfolio with clinical and pre-clinical compounds and programmes. These assets include two anti-HCV compounds which both target the novel NS5a protein, including A-831 in Phase I.
Arrow's most advanced compound is RSV604, currently in Phase II clinical development and partnered with Novartis. RSV604 is a first-in-class, small molecule, oral anti-RSV compound.
Comment Preview